ReviewCurrent psychiatry reports2005
Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?
Review in Current psychiatry reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].Der Nervenarzt · 2008Pooled it
- Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder.Schizophrenia bulletin · 2025Trial
- Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.Current addiction reports · 2014Article
- Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC.Schizophrenia research · 2014Article
- Impact of substance use disorder on presentation and short-term course of schizophrenia.Psychiatry journal · 2014Article
- Negative symptoms are associated with less alcohol use, craving, and "high" in alcohol dependent patients with schizophrenia.Schizophrenia research · 2008Article
- Substance abuse and schizophrenia: pharmacotherapeutic intervention.Journal of substance abuse treatment · 2008Review
- Pharmacotherapy for schizophrenia and co-occurring substance use disorders.Neurotoxicity research · 2007Review
- Current research on co-occurring substance-use disorder in schizophrenia.Schizophrenia bulletin · 2006Article
- Concomitant medication of psychoses in a lifetime perspective.Human psychopharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Substance use disorders (SUDs) are highly prevalent and are associated with poor outcomes among individuals with schizophrenia. Integrating treatments for both disorders improves outcomes. Numerous individual pharmacologic and psychosocial treatments have shown effectiveness at reducing substance use in individuals with a primary diagnosis of schizophrenia and co-occurring substance use disorders. Of these treatments, medications such as certain atypical antipsychotics and naltrexone, and psychosocial treatments such as contingency management, seem to be particularly promising. The development and evaluation of psychopharmacologic and psychosocial treatments for SUDs in schizophrenia would benefit from a better understanding of the neurobiological mechanisms underlying the effectiveness of such treatments. Several theories have been put forth to explain the heightened risk for SUDs in schizophrenia. Of these, brain reward circuitry dysfunction, hypothesized to be etiologically important in SUDs, may be an especially salient target for treatments aimed at the reduction of substance use in patients with schizophrenia. We review current pharmacologic and psychosocial treatments for SUDs in schizophrenia, and theoretical mechanisms underlying the increased risk for SUDs in this population. We propose that effective treatments may in part work through the modulation of brain reward circuitry dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.